CN103223069A - Traditional Chinese medicine composition for treating hepatitis - Google Patents
Traditional Chinese medicine composition for treating hepatitis Download PDFInfo
- Publication number
- CN103223069A CN103223069A CN2013101870248A CN201310187024A CN103223069A CN 103223069 A CN103223069 A CN 103223069A CN 2013101870248 A CN2013101870248 A CN 2013101870248A CN 201310187024 A CN201310187024 A CN 201310187024A CN 103223069 A CN103223069 A CN 103223069A
- Authority
- CN
- China
- Prior art keywords
- parts
- hepatitis
- chinese medicine
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a traditional Chinese medicine composition for treatinghepatitis and relates to the field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 parts of rhizoma alismatis, 6 parts of oriental wormwood, 10 parts of pseudo-ginseng, 10 parts of szechwan lovage rhizome, 20 parts of fructus aurantii, 20 parts of hawthorn, 10 parts of radix bupleuri, 15 parts of scutellaria baicalensis, 30 parts of rhizoma atractylodis, 5 parts of white paeony root, 6 parts of salviae miltiorrhizae, 15 parts of common leafflower herb with root, 10 parts of burdock, 5 parts of Chinese gall and 10 parts of liquorice. The traditional Chinese medicine composition has good therapeutic effect on fatty liver hepatitis, hepatitis caused by an organic solvent or medicine and viral hepatitis B and has an obvious clinical popularization value.
Description
Technical field
The present invention relates to the Chinese medicine technical field, be specifically related to a kind of Chinese medicine composition for the treatment of hepatitis.
Background technology
Hepatitis, typically refer to by multiple paathogenic factor---as virus, antibacterial, parasite, chemical toxicant, medicine and poisonous substance, ethanol etc., the infringement liver, make the cell of liver be damaged, the function of liver suffers damage, it can cause a series of malaise symptoms of health pearl, and liver function index is unusual.The pathological changes of various hepatitis mainly is at liver, and some similar clinical manifestations are all arranged, and often there is tangible difference aspect such as infringement outside nosetiology, serology, damage mechanism, clinical process and prognosis, liver.
Hepatitis comes can be divided into viral hepatitis, drug induced hepatitis, alcoholic hepatitis, toxic hepatitis etc. usually according to the cause of disease; Can be divided into acute hepatitis, chronic hepatitis etc. according to course of disease length; Clinically to the diagnosis of hepatitis, normally combine above-mentioned several different methods classification.Relatively more unified at present is classified as follows:
1, viral hepatitis: the hepatitis that causes by virus according to its virus series difference be divided into first, second, third, fourth, penta and heptan totally six types of viral hepatitis.Can cause liver cell swelling, be to spread in the world extensively, endangers one of very big infectious disease.In China, hepatitis B is propagated wider.
2, fat hepatitis: can be divided into alcoholic fatty liver inflammation and non-alcoholic stellato-hepatitis again according to its disease reason.The liver anatomic image and the alcoholic hepatitis of non-alcoholic stellato-hepatitis closely similar (cell of fat drop, inflammation), how it is transformed by fatty liver.Fatty liver is meant because the pathological changes of the interior fatty overheap of the hepatocyte that a variety of causes causes.The positive serious threat compatriots' of fatty liver disease health becomes the second largest hepatopathy that is only second to viral hepatitis, has been acknowledged as the common cause of disguised liver cirrhosis.
3, drug induced hepatitis: many medicines can cause hepatitis, have cancelled its permission such as the U.S. in 2000 because the medicine for treating diabetes troglitazone can cause hepatitis.Other medicine relevant with hepatitis has: Pien Tze Huang, Hal, methyldopa, isoniazid, rifampicin and pyrazinamide, phenytoin zinc and valproic acid, zidovudine, ketoconazole, nifedipine, ibuprofen and indomethacin, amitriptyline, amiodarone, nitrofurantoin, oral contraceptive, gallbladder are pluged with molten metal alcohol, azathioprine.Carbon tetrachloride, chloroform, acetylene trichloride and other all organochlorines can cause fat hepatitis, and some diseases of metabolism also can cause multi-form hepatitis.
4, autoimmune hepatitis: autoimmune hepatitis is more rare, and many and other autoimmune disease accompanies, and is one of disease of newly determining in recent years.This disease has higher sickness rate in American-European countries, accounts for the 10%-15% of chronic hepatopathy as this disease of the U.S., and China also day by day increases for the report of this disease at present.
Since the 80's of 20th century, the hepatitis especially sickness rate of fat hepatitis is on the increase, and the morbidity crowd is rejuvenation trend gradually.This disease is often out in the cold in early days in daily life, often delays abnormal liver function, hepatic fibrosis, even develops into liver cirrhosis.Though on the market Western medicine that much is used for treating hepatitis is arranged now, because these Western medicine mostly have potential hepatotoxicity, and action target spot is single, therefore can not obtain the effect of satisfied treatment.Researching and developing the effective medicine of a kind of hepatitis is of great practical significance.
Chinese medicine hepatitis historical of long standing and well established, and as an importance of modern hepatopathy Comprehensive Treatment, more and more receive publicity in recent years.Make a general survey of the research direction of world's new drug, mainly be single chemicals of research and development and preparation thereof the eighties in the past, begins to develop biotechnology and natural medicinal plants after the eighties, and the drug research direction is tending towards multiformity.In conjunction with the modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened the preparation that extraction and/or compatibility make, its side effect is little, and is safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
Chinese medicine thinks that the ill reason of hepatitis mainly is positive QI-insufficiency.Owing to eating and drinking without temperance, forfeit one's integrity, damaged taste and can not removing dampness, give birth in damp and hot, be stranded the damage of the spleen liver, cause the liver and gall incoordination between the spleen and stomach, thereby added hurriedly damage healthy energy, caused the generation of hepatitis.In addition, because positive QI-insufficiency, as easy as rolling off a log infection epidemic disease poison is so the main cause of hepatitis epidemic is exactly popular bad dietary habit.In other words, country can not comply with the dietary habit of consumer fully, and the guiding correct in addition to common people's daily life is only prophylactic key.
Still there is not very effectively Drug therapy at present hepatitis, first purpose of the present invention is to provide a kind of Chinese medicine composition for the treatment of hepatitis, and this Chinese medicine composition has good therapeutic effect aspect treatment viral hepatitis, fat hepatitis and the drug induced hepatitis.Chinese medicine composition of the present invention is made by the raw material of following weight portion: 10 parts of Rhizoma Alismatis, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 15 parts of Herba Phyllanthi Urinariaes, 10 parts of Fructus Arctiis, 5 parts of Galla Chinensiss, 10 parts in Radix Glycyrrhizae.
Rhizoma Alismatis (rhizome) is again one of traditional Chinese medicine.Theory of Chinese medical science thinks that it is cold in nature, has the effect of promoting diuresis to eliminate damp pathogen; Cure mainly expel the heat-evil treating stranguria, dysuria, the puckery pain of pyretic stranguria, edema distension, have loose bowels, disease such as dizziness due to fluid-retention.Modern medicine study, Rhizoma Alismatis can reduce serum total cholesterol and triacylglycerol content, slow down atherosclerosis and form; Rhizoma Alismatis and preparation modern times thereof also are used for the treatment of auditory vertigo, dyslipidemia, seminal emission, fatty liver and diabetes etc.
Herba Artemisiae Scopariae has the effect of clearing away heat-damp and promoting diuresis, jaundice eliminating, cures mainly diseases such as jaundice, dysuria, eczema pruritus, infectious jaundice type hepatitis.Modern pharmacology research Herba Artemisiae Scopariae has function of gallbladder promoting, effects such as liver function protecting, analgesic, antiinflammatory, blood fat reducing, blood pressure lowering, coronary dilating.
Radix Notoginseng has removing stasis to stop bleeding, the effect of promoting blood circulation and detumescence analgesic therapy; The hot temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go diffusing, the up top, mountain peak that reaches; Go into blood system again, the descending sea of blood that reaches.The blood circulation promoting and blood stasis dispelling action range, the suitable various diseases of stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control diseases such as wind syndrome of head headache, rheumatic arthralgia.
Fructus Aurantii nature and flavor hardship, acid, be slightly cold, return lung, spleen, liver, stomach, large intestine channel, function cures mainly diseases such as weight behind septum pectorale feeling of fullness, distending pain over the hypochondrium, accumulation of food in the stomach and intes tine due to indigestion, distension and fullness in the abdomen, the dysentery, proctoptosis, uterine prolapse.Fructus Crataegi does medicinal with fruit, slightly warm in nature, and sour in the mouth is sweet, goes into spleen, stomach, Liver Channel, and the function of promoting digestion and invigorating the stomach, activating blood circulation to dissipate blood stasis, convergence dysentery relieving is arranged.To the long-pending phlegm retention of meat, feeling of fullness acid regurgitation, dysentery hemorrhoidal hamorrhage, lumbago hernia, puerperal after-pains, lochiorrhea, children's's breast food stagnate etc., all effective in cure." herbal classic " cloud: sour in the mouth, air cooling, so see its can help digestion long-pending, clots absorbing blood, then gas is non-cold.Having stagnates then becomes dysentery, prolonged lochia, and holding in lunar part then is after-pains.Fructus Crataegi can go into the taste removing food stagnancy and stagnate, and stagnated blood looses.Radix Bupleuri cold nature, bitter in the mouth, suffering are returned Liver Channel, gallbladder meridian, have expelling pathogenic factors from the exterior and expel the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, the effect of elevate a turnable ladder yang-energy." Bencao Jingshu ": " Radix Bupleuri is the shaoyang channel medicine administered to bring out the cold.
Radix Scutellariae another name Radix Scutellariae, tsuchikane tea root are labiate, are used as medicine with root.Heat clearing and damp drying is arranged, and removing heat from blood is antiabortive, detoxicating functions.Cure mainly diseases such as epidemic febrile disease, upper respiratory tract infection, cough due to lung-heat, damp and hot jaundice, pneumonia, dysentery, hemoptysis, conjunctival congestion, frequent fetal movement, hypertension, carbuncle furuncle.Rhizoma Atractylodis have drying damp and strengthening spleen, expelling wind and cold, and the effect that makes eye bright is used for wet resistance taste, distension and fullness in the abdomen, the cold-damp leucorrhea, damp-warm diseases and damp invasion of lower energizer, foot swelling and pain in knee, flaccidity are soft unable.Controlling wet resistance taste, and seeing the thick disease such as turbid of distension and fullness in the abdomen, inappetence, fatigue and weakness, white and greasy fur, normal and compatibility application such as Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae.
The Radix Paeoniae Alba goes into liver, spleen channel, has nourishing blood to suppress the hyperactive liver, slow middle pain relieving, and yin fluid astringing is received the effect of antiperspirant.Cure mainly the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, diseases such as leukorrhagia.Radix Salviae Miltiorrhizae has another name called Radix Salviae Miltiorrhizae, Radix Salviae Miltiorrhizae, Arisaema balansae Engl. etc.Be the dicotyledon Labiatae, dry root and rhizome.Main product in Anhui, ground such as Henan, Shaanxi.Effect: promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind.
Rhizoma Alismatis and Herba Artemisiae Scopariae can play dispelling phlegm and eliminating dampness, protect the liver jaundice eliminating.Radix Notoginseng, Rhizoma Chuanxiong blood circulation promoting and blood stasis dispelling, removing mass collateral dredging; Fructus Aurantii and Fructus Crataegi can promoting digestion and invigorating the stomach, eliminate the distension and fullness in the abdomen symptom.The tender enough heat clearing and damp drying of Radix Bupleuri and Radix Scutellariae, eliminating stagnation are induced sweat.The Radix Paeoniae Alba and Radix Salviae Miltiorrhizae can nourishing blood to suppress the hyperactive liver, nourishing blood to tranquillize the mind.The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription.All medicines share, altogether the effect of long memorial liver resolving depression, spleen invigorating food stagnation removing, activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness.
Herba Phyllanthi Urinariae is dicotyledon medicine euphorbia plant Cacumen Securinegae Suffruticosae or whole herb with root, has the effect of calming liver and clearing heat, promoting diuresis to remove toxic substance, cures mainly enteritis clinically, diseases such as dysentery, infectious hepatitis, oedema due to nephritis, innominate toxic swelling.Prior art proof Herba Phyllanthi Urinariae has the effect of hepatitis virus resisting and hepatic cholagogic, and can suppress and reverse hepatic fibrosis to a certain extent.Fructus Arctii is called as Fructus Arctii, originates in China, and Compendium of Material Medica claims that " Fructus Arctii " (claiming Fructus Arctii again) is 2 years these plants of SHENGCAO, and its son, its root all can be used as medicine, also edible, and " Bencao Jingshu " is called " wind that looses removes thermal detoxification three key medicines ".Prior art proves that it has significant anti-bacteria and anti-virus effect, and the immunocompetence of the remarkable enhancing body of energy.Galla Chinensis have astringe the lung, hidroschesis, astringing intestine to stop diarrhea, controlling nocturnal emission with astringent drugs, hemostasis, antidotal effect, clinically cure mainly diseases such as chronic cough of deficiency lung spontaneous sweating, chronic dysentery chronic diarrhea, proctoptosis seminal emission, carbuncle furuncle, itself and Herba Phyllanthi Urinariae logotype can strengthen its antiviral effect.Herba Phyllanthi Urinariae, Fructus Arctii, three kinds of medicine logotypes of Galla Chinensis, the remarkable immunocompetence of enhancing body not only, and can aspect hepatitis virus resisting, have remarkable synergism.The present invention confirms when the weight part ratio Herba Phyllanthi Urinariae: Fructus Arctii: Galla Chinensis=3:2:1, its collaborative hepatitis virus resisting is the strongest.
The method for preparing Chinese medicine composition of the present invention is as follows: get each medical material of above-mentioned weight portion, add the 5-15 water doubly of medical material gross weight, soaked 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and this relative density is the testing result under 60 degrees centigrade, adds ethanol and is 60-90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, promptly.The above-mentioned Chinese medicine composition of the present invention can further be prepared into pharmaceutical preparation commonly used clinically, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, the purposes of promptly above-mentioned Chinese medicine composition in preparation treatment or prevention hepatitis medicament.Wherein said hepatitis can be the damaging hepatitis or the hepatitis B of fat hepatitis, organic solvent or drug-induced.The embodiment of the invention 4 is by investigating the treatment experiment of Chinese medicine composition of the present invention to rat non-alcoholic stellato-hepatitis model, find that Chinese medicine composition provided by the invention can obviously reduce the AST and the ALT of fat hepatitis rat model, TG, TC and the LDL-C of fatty rat model can be significantly reduced, and the liver index of rat model can be significantly reduced.This acts on comprehensively when showing Chinese medicine composition of the present invention to treatment or prevention fat hepatitis disease, has obvious synergism, has obtained unforeseeable curative effect of medication.Its therapeutic effect to fat hepatitis is better than existing medicine silibinin.The embodiment of the invention 5 is by investigating Chinese medicine composition of the present invention causes the chmice acute liver injury model to carbon tetrachloride treatment experiment, find that Chinese medicine composition of the present invention can significantly reduce the ALT and the AST of mouse model, thereby can have significant therapeutical effect hepatic injury due to the organic solvent or drug induced hepatitis.The embodiment of the invention 6 is by investigating the clinical therapeutic efficacy of Chinese medicine composition of the present invention to hepatitis B patient, find that Chinese medicine composition medication of the present invention can significantly reduce patient's AST, ALT, SB, γ-GT, A/G value after two months, embody excellent antiphlogistic effects and liver protecting effect, and significantly be better than matched group; The HbcAg(+ of traditional Chinese medicine composition for treating group of the present invention) negative conversion rate, HbeAg(+) negative conversion rate, HBV-DNA(+) negative conversion rate also increases significantly with respect to matched group.
In a word, the present invention compared with prior art has the activity of fine treatment hepatitis, and can the present invention be pure Chinese medicinal preparation, to human body particularly to the liver avirulence.The present invention is during as the treating hepatitis drug use, and drug effect is comprehensive, in dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, can also obtain the effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness, and sb.'s illness took a favorable turn can to make hepatitis rapidly; And Chinese medicine composition preparation of the present invention is simple, and nontoxic substantially, raw material is easy to get, and is suitable for popular use, has good application prospects.
The specific embodiment
Below further describe the present invention by the specific embodiment, but the present invention is not limited only to following examples.Within the scope of the invention or in not breaking away from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they all are regarded as comprising within the scope of the present invention.
First, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 15 parts of Herba Phyllanthi Urinariaes, 10 parts of Fructus Arctiis, 5 parts of Galla Chinensiss, 10 parts in Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 5 times water of medical material gross weight, soaked 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 75%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, packing, flowing steam sterilization 35min promptly gets mixture.
Embodiment 2 Chinese medicine composition tablets of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 15 parts of Herba Phyllanthi Urinariaes, 10 parts of Fructus Arctiis, 5 parts of Galla Chinensiss, 10 parts in Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 10 times water of medical material gross weight, soaked 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 80%(v/v) to containing the alcohol amount, left standstill 24 hours, and got supernatant, reclaim ethanol to concentrating, vacuum drying, granulation, tabletting are promptly.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: 10 parts of Rhizoma Alismatis, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 15 parts of Herba Phyllanthi Urinariaes, 10 parts of Fructus Arctiis, 5 parts of Galla Chinensiss, 10 parts in Radix Glycyrrhizae.
Preparation method: get each medical material of above-mentioned components by weight percent, add 8 times water of medical material gross weight, soaked 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression are concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees centigrade, add ethanol and be 90%(v/v to containing the alcohol amount), left standstill 24 hours, get supernatant, reclaim ethanol to concentrating, vacuum drying is granulated, and is promptly encapsulated.
Second portion, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
Embodiment 4 Chinese medicine compositions of the present invention are to the treatment of non-alcoholic stellato-hepatitis
AST mainly is present in nucleus and the mitochondrion, is released into blood when the hepatocyte obvious damage, and its level raises and shows the obvious degeneration necrosis of hepatocyte; GST (glutathione S-transferase) belongs to II phase enzyme in biotransformation enzyme system, participate in association reaction, and cell membrane integrity is destroyed during hepatic injury, and GST can be released into blood in a large number, and the clear GST of hyperamization increases; Wang Hui et al studies show that, serum GST activity change has the diagnostic meaning for multiple hepatic injury, and has good parallel relation between hepatic tissue pathology change, the Serum ALT activity change, sensitiveer, more special and have a higher accuracy than ALT, existing at present part hospital with serum GST as one of liver function diagnosis index.
1, non-alcoholic stellato-hepatitis Preparation of model
The SD rat, male, body weight 220 ± 20g adopts the method modeling of irritating the high lipoprotein emulsion associating of stomach lumbar injection tetracycline.Except that the normal control group, all the other each group gave lumbar injection tetracycline 150mg/kg on the 1st day in modeling, and the back is every 6d lumbar injection tetracycline 110mg/kg1 time, totally 6 times.Except that normal group, every group in the high lipoprotein emulsion of every morning 9:30 filling stomach, dosage 10mlkg
-1D
-1High lipoprotein emulsion prescription: Adeps Sus domestica 20g, cholesterol 10g, fructose 5g, sucrose 5g, cholate 1g, sodium glutamate 1g, propylene glycol 15ml, a little soil temperature 80, distilled water is settled to 100ml.Irritating stomach continues 8W for high fat breast.
2, grouping and administration
After the rat model adaptability raised for 1 week, be divided into normal group, model group and administration group at random, specifically grouping situation sees the following form, 10 every group.Irritate the stomach medicine every afternoon during 14:30, and dosage is as follows:
The normal control group: the filling stomach gives the distilled water with volume;
Model control group: the filling stomach gives the distilled water with volume;
Silibinin group: irritate stomach and give 25mg/(kg.d) silibinin;
Low dose group: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 0.1 g/(kg.d);
Middle dosage group: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 1 g/(kg.d);
High dose group: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 10 g/(kg.d).
3, detect index
After the last administration, the pentobarbital sodium anesthetized rat is dissected, and the abdomen cardinal vein is got the hematometry biochemical indicator, gets liver and weighs.
3.1. liver function
Result of the test shows (seeing table 1 for details), fat hepatitis model group rat blood serum ALT, AST content are compared with normal group significantly and are raise, the rat blood serum ALT of each administration group, AST content are compared obvious decline with model group, especially, each dosage group of compound recipe is compared with model group has utmost point significant difference, compared utmost point significant difference with the silibinin group, this explanation Chinese medicine composition of the present invention each Chinese medicine has been obtained synergitic effect on to the prevention of rat fat hepatitis or treatment.
Table 1 Chinese medicine composition of the present invention is to the influence of rat model liver function
Compare with model group,
*P＜0.05; Compare with model group,
*P＜0.01; Compare with the silibinin group,
#P＜0.05; Compare with the silibinin group,
##P＜0.01;
3.2 blood fat
Result of the test shows (seeing table 2 for details), the level of T-CHOL, triglyceride, HDL-C and the low-density lipoprotein cholesterol of each dosage group of compound recipe has been compared significant difference or utmost point significant difference with rat fat hepatitis model group, compare with silibinin group or low molecular weight heparin group and also to have significant difference or utmost point significant difference (except the hdl level), Chinese medicine use in conjunction in this explanation Chinese medicine composition of the present invention, on rat fat hepatitis model, on reduction TG, TC and LDL-C, obtained good synergism.
Table 2 Chinese medicine composition of the present invention is to the influence of rat fat
Compare with model group,
*P＜0.05; Compare with model group,
*P＜0.01;
Compare with the silibinin group,
#P＜0.05; Compare with the silibinin group,
##P＜0.01;
3.3. liver index
Result of the test shows (seeing table 3 for details), fat hepatitis model group rats'liver index has been compared utmost point significant difference with normal group, the liver index of the rat of each administration group has been compared utmost point significant difference with model group, especially, each dosage group of compound recipe has been compared significant difference or utmost point significant difference with pyrrole group or Low molecular heparin group, each Chinese medicine of this explanation Chinese medicine composition of the present invention has been obtained good synergism on this index of reduction liver index on rat fat hepatitis model.
Table 3 Chinese medicine composition of the present invention is to the exponential influence of Rats Organs and Tissues
Compare with normal group,
$P＜0.05; Compare with normal group,
$$P＜0.01;
Compare with model group,
*P＜0.05; Compare with model group,
*P＜0.01;
Compare with the silibinin group,
#P＜0.05; Compare with the silibinin group,
##P＜0.01.
Embodiment 5 Chinese medicine compositions of the present invention cause the therapeutical effect of chmice acute liver injury model to carbon tetrachloride
Carbon tetrachloride hepatic injury is one of present international hepatitis model commonly used, and its poisoning mechanism mainly is that the generation free radical caused the membrane lipid peroxidating after carbon tetrachloride entered body, membrane structure and functional completeness is destroyed, thereby cause cytotoxic death.
1, material and method
1.1 material
Healthy ♂ kunming mice, body constitution amount 18-22 g, institute provides by Hubei Province's medical courses in general; 1-chloro-2,4-dinitro benzene (CDNB) and reduced glutathion (GSH) are the Sigma product, AST measures test kit, purchase in Shanghai Rongsheng Bioisystech Co., Ltd (lot number: 9906017), all the other reagent are commercially available analytical pure product. day island proper Tianjin UV-3000 dual-wavelength double beam spectrophometer UV-752C ultra-violet and visible spectrophotometer (Shanghai the 3rd analytical tool factory).
1.2 model preparation and medication
Be divided into high, normal, basic group of normal saline matched group (control), CCL4 model group, Chinese medicine composition of the present invention after healthy kunming mice fasting 24 h weigh at random, other each groups are duplicated liver injury model with 500 mL/L CCL4 Oleum Arachidis hypogaeae semen by 0.1 ml/10 g filling stomach except that matched group.Each organizes administering mode and dosage is as follows:
Matched group: irritate stomach and give isopyknic 10 mL/kg normal saline
Model group: irritate stomach and give isopyknic 10 mL/kg normal saline
The high group of Chinese medicine: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 0.1 g/(kg.d);
Organize in the Chinese medicine: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 1 g/(kg.d);
The low group of Chinese medicine: irritate stomach and give the embodiment of the invention 1 prepared Chinese medicine composition mixture, crude drug dosage 10 g/(kg.d);
Each drug treatment group is administered once every day, successive administration 10 days.Respectively organizing mice before the last administration weighs, 6 h put to death mice after the administration, serum is collected in blood-letting, and cut open the belly immediately and get same leaf hepatic tissue and clean with the ice normal saline, in-30 ℃ of frozen surveys fully of refrigerator. with CDNB is substrate, measures serum GST activity with Tianjin, island UV-3 000 dual-wavelength double beam spectrophometer. press AST and measure test kit description mensuration serum AST.Get murine liver tissue and make 10 % tissue homogenates, measure MDA content with the thiobarbituricacid method with the ice normal saline.Each treatment group experimental data adopts to be represented with x ± s, relatively with the F check, relatively checks with q in twos between group between many groups.
2, experimental result and analysis
Table 4 Chinese medicine composition of the present invention is to the influence of mouse model liver function
Compare with model group,
*P＜0.05; Compare with model group,
*P＜0.01;
Result of the test shows (seeing table 4 for details), model group mice serum ALT, AST content are compared with normal group significantly and are raise, each administration group mice serum ALT, AST content are compared obvious decline with model group, especially, each dosage group of compound recipe is compared with model group has utmost point significant difference, compared utmost point significant difference with the silibinin group, this explanation Chinese medicine composition of the present invention each Chinese medicine has been obtained synergitic effect on to the prevention of the hepatic injury of chmice acute hepatic injury or drug-induced or treatment.
Embodiment 6 Chinese medicine compositions of the present invention are to the clinical therapeutic efficacy of hepatitis B patient
1, clinical data
1.1 physical data
100 routine patients are divided into two groups at random in the ratio of 3:1, and 75 examples are organized in treatment, male 45 examples, women 30 examples, 18 years old-60 years old age, average 42 years old.Matched group 25 examples, male 15 examples, women 10 examples, 17 years old-58 years old age, average 43 years old.Patient's sex age ratio does not have significant difference, has comparability.
1.2 diagnostic criteria
Unite the viral hepatitis of revision according to Chinese Medical Association and hepatopathy association of parasitology branch and prevent and treat scheme, be diagnosed as chronic hepatitis.
1.3 the clinical research guideline of tcm diagnosis standard reference new Chinese medicine treatment viral hepatitis.
1.4 exclusion standard
1) autoimmune liver disease; 2) unstable diabetes; 3) gravid woman; 4) renal function goes down; 5) ethylism hepatitis; 6) cardiovascular and cerebrovascular disease, psychosis etc.
2, Therapeutic Method
Use the Chinese medicinal composition capsules of the present invention for preparing by the embodiment of the invention 3 to the patient, each 3, every day 3 times is oral, the about 3.5g of every capsules folding crude drug.Serveing on 2 months is 1 course of treatment, indexs such as check liver function, two double, renal function; Matched group adopts giant knotweed containing capsule for treating hepatitis B (production of Jiangsu Province Tianzhao Pharmaceutical Ind Co., Ltd., Huai'an), and each 5, every day three times, check in oral 2 months.
Observation item: check liver function, HBV-DNA and hepatitis B before and after the medication respectively two double for 1 time.HBV-DNA adopts the PCR method, and liver function adopts full automatic biochemical apparatus to detect.
Statistical method: measurement data is checked with t, the enumeration data X 2 test.
3, therapeutic outcome
3.1 changes of liver function (relatively seeing Table 5) before and after two groups of treatments
Changes of liver function before and after table 5 Chinese medicine composition of the present invention and the treatment of control group
Contrast before and after the treatment group:
*P＜0.01 and contrasts after the treatment of control group:
#P＜0.05.
As can be seen from Table 5; there is significant difference before and after matched group and the treatment of treatment group medicine liver function indexes; this shows that two groups of medicines all embody significant antiphlogistic effects and obvious liver function-protecting effect; there are significant difference in liver function index after the treatment of wherein treatment group and the liver function index after the treatment of control group, show that the antiphlogistic effects of Chinese medicine composition of the present invention and liver function protection effect will significantly be better than matched group.
3.2 HbcAg, HbeAg, HBV-DNA change relatively (before the treatment back/treatment) before and after two groups of treatments
Table 6 Chinese medicine composition of the present invention is to the influence of hepatitis B virus negative conversion rate
With contrast after the treatment of control group:
#P＜0.05,
##P＜0.01.
As can be seen from the above table, the HbcAg(+ of treatment group) negative conversion rate, HbeAg(+) negative conversion rate, HBV-DNA(+) negative conversion rate compares the difference that has significance or utmost point significance with matched group, and this shows that Chinese medicine composition of the present invention obtained very good therapeutic effect to the treatment of hepatitis B.
Claims (3)
1. a Chinese medicine composition for the treatment of hepatitis is characterized in that being made by the raw material of following weight portion: 10 parts of Rhizoma Alismatis, 6 parts of Herba Artemisiae Scopariaes, 10 parts of Radix Notoginseng, 10 parts of Rhizoma Chuanxiongs, 20 parts of Fructus Aurantiis, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts of Radix Scutellariaes, 30 parts of Rhizoma Atractylodis, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 15 parts of Herba Phyllanthi Urinariaes, 10 parts of Fructus Arctiis, 5 parts of Galla Chinensiss, 10 parts in Radix Glycyrrhizae.
2. the Chinese medicine composition of treatment hepatitis as claimed in claim 1 is characterized in that described pharmaceutical composition is mixture, tablet or capsule.
3. the preparation method of the Chinese medicine composition of treatment hepatitis as claimed in claim 1 or 2, it is characterized in that may further comprise the steps: get each medical material, the 5-15 water doubly that adds the medical material gross weight, soaked 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, this relative density is the testing result under 60 degrees centigrade, adding ethanol is 60-90% to containing alcohol amount percent by volume, leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrating, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101870248A CN103223069A (en) | 2013-05-20 | 2013-05-20 | Traditional Chinese medicine composition for treating hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101870248A CN103223069A (en) | 2013-05-20 | 2013-05-20 | Traditional Chinese medicine composition for treating hepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103223069A true CN103223069A (en) | 2013-07-31 |
Family
ID=48833865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101870248A Pending CN103223069A (en) | 2013-05-20 | 2013-05-20 | Traditional Chinese medicine composition for treating hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103223069A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104524171A (en) * | 2014-12-30 | 2015-04-22 | 陈满锦 | Application of traditional Chinese medicine preparation in preparing medicine for treating hepatitis |
| CN104771589A (en) * | 2015-04-27 | 2015-07-15 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating fatty liver and application thereof |
| CN104888155A (en) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating fatty liver combined hyperlipidemia and preparation method thereof |
| CN105726998A (en) * | 2014-03-24 | 2016-07-06 | 孙峰 | Preparation method of medicine for treating posthepatitic syndrome |
| CN106420971A (en) * | 2016-12-13 | 2017-02-22 | 蓝庆流 | Traditional Chinese medicine composition for treating hepatitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283956A (en) * | 2011-07-31 | 2011-12-21 | 李金伟 | Orally administered drug for treating chronic hepatitis |
| CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
| CN102824482A (en) * | 2012-09-25 | 2012-12-19 | 陈兴旺 | Traditional Chinese medicine composition for treating icteric hepatitis |
-
2013
- 2013-05-20 CN CN2013101870248A patent/CN103223069A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283956A (en) * | 2011-07-31 | 2011-12-21 | 李金伟 | Orally administered drug for treating chronic hepatitis |
| CN102727686A (en) * | 2012-07-20 | 2012-10-17 | 杨献华 | Traditional Chinese medicine composition for treating fatty liver |
| CN102824482A (en) * | 2012-09-25 | 2012-12-19 | 陈兴旺 | Traditional Chinese medicine composition for treating icteric hepatitis |
Non-Patent Citations (1)
| Title |
|---|
| 孔祥廉等: "中医药治疗乙型病毒性肝炎研究进展", 《时珍国医国药》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726998A (en) * | 2014-03-24 | 2016-07-06 | 孙峰 | Preparation method of medicine for treating posthepatitic syndrome |
| CN104524171A (en) * | 2014-12-30 | 2015-04-22 | 陈满锦 | Application of traditional Chinese medicine preparation in preparing medicine for treating hepatitis |
| CN104771589A (en) * | 2015-04-27 | 2015-07-15 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating fatty liver and application thereof |
| CN104888155A (en) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating fatty liver combined hyperlipidemia and preparation method thereof |
| CN106420971A (en) * | 2016-12-13 | 2017-02-22 | 蓝庆流 | Traditional Chinese medicine composition for treating hepatitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6455078B1 (en) | Medicinal herbal composition for treating liver diseases and HIV | |
| CN102727686B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN104042802A (en) | Traditional Chinese medicine composition capable of treating fatty liver | |
| CN104338043B (en) | A kind of medicine for improving immunity and preparation method thereof | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN103599495A (en) | Chinese medicinal composition for treatment of hepatitis B | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
| CN101020027B (en) | Medicine composition for preventing and treating AIDS and its preparation process and use | |
| CN107029173B (en) | Pharmaceutical composition for treating primary liver cancer | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN106334171A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof | |
| CN104127826A (en) | Traditional Chinese medicine composition for treating chronic alcoholic liver disease | |
| CN107898972A (en) | A kind of Chinese medicine composition and application for being used to treat liver diseases | |
| CN103948736B (en) | The compound Chinese medicinal preparation for the treatment of hepatocarcinoma and production method thereof | |
| CN104510912B (en) | A kind of Chinese medicine and preparation method for the treatment of qi stagnation and blood stasis type chronic hepatitis B | |
| CN105232609A (en) | Traditional Chinese medicine combination treating functional dyspepsia | |
| CN105381410A (en) | Traditional Chinese medicinal preparation for treating hepatitis | |
| CN104645079A (en) | Traditional Chinese medicine for treating post-stroke limb numbness | |
| CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof | |
| CN104887852A (en) | Traditional Chinese medicine for treating blood deficiency type postpartum wind and preparation method thereof | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130731 |